These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1678 related items for PubMed ID: 30052812

  • 1. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R, Hinz R, Biju M, Kuruvilla T, Brooks DJ, Edison P.
    Brain; 2018 Sep 01; 141(9):2740-2754. PubMed ID: 30052812
    [Abstract] [Full Text] [Related]

  • 2. Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects.
    Dani M, Wood M, Mizoguchi R, Fan Z, Edginton T, Hinz R, Win Z, Brooks DJ, Edison P.
    J Alzheimers Dis; 2019 Sep 01; 70(2):455-465. PubMed ID: 31256120
    [Abstract] [Full Text] [Related]

  • 3. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA, Langhough RE, Zammit MD, Clark L, Chin N, Christian BT, Betthauser TJ, Johnson SC.
    Brain; 2024 Jun 03; 147(6):2144-2157. PubMed ID: 38667631
    [Abstract] [Full Text] [Related]

  • 4. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge.
    Cousins O, Schubert JJ, Chandra A, Veronese M, Valkimadi P, Creese B, Khan Z, Arathimos R, Hampshire A, Rosenzweig I, Ballard C, Corbett A, Aasland D, Velayudhan L, O'Neill M, Collier D, Awais R, Sander K, Årstad E, Howes O, Turkheimer F, Hodges A.
    J Neuroinflammation; 2023 Nov 21; 20(1):272. PubMed ID: 37990275
    [Abstract] [Full Text] [Related]

  • 5. Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Maass A, Berron D, Harrison TM, Adams JN, La Joie R, Baker S, Mellinger T, Bell RK, Swinnerton K, Inglis B, Rabinovici GD, Düzel E, Jagust WJ.
    Brain; 2019 Aug 01; 142(8):2492-2509. PubMed ID: 31199481
    [Abstract] [Full Text] [Related]

  • 6. An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Fan Z, Brooks DJ, Okello A, Edison P.
    Brain; 2017 Mar 01; 140(3):792-803. PubMed ID: 28122877
    [Abstract] [Full Text] [Related]

  • 7. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL.
    Brain; 2014 Jun 01; 137(Pt 6):1762-71. PubMed ID: 24681664
    [Abstract] [Full Text] [Related]

  • 8. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study.
    Ismail R, Parbo P, Madsen LS, Hansen AK, Hansen KV, Schaldemose JL, Kjeldsen PL, Stokholm MG, Gottrup H, Eskildsen SF, Brooks DJ.
    J Neuroinflammation; 2020 May 06; 17(1):151. PubMed ID: 32375809
    [Abstract] [Full Text] [Related]

  • 9. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ, Devous MD, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators.
    Brain; 2017 Mar 01; 140(3):748-763. PubMed ID: 28077397
    [Abstract] [Full Text] [Related]

  • 10. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2016 May 01; 139(Pt 5):1551-67. PubMed ID: 26962052
    [Abstract] [Full Text] [Related]

  • 11. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O'Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2017 Dec 01; 140(12):3286-3300. PubMed ID: 29053874
    [Abstract] [Full Text] [Related]

  • 12. Combined Neuroinflammation and Amyloid PET Markers in Predicting Disease Progression in Cognitively Impaired Subjects.
    Leng F, Hinz R, Gentleman S, Dani M, Brooks DJ, Edison P.
    J Alzheimers Dis; 2024 Dec 01; 100(3):973-986. PubMed ID: 39031352
    [Abstract] [Full Text] [Related]

  • 13. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study.
    Parbo P, Ismail R, Sommerauer M, Stokholm MG, Hansen AK, Hansen KV, Amidi A, Schaldemose JL, Gottrup H, Brændgaard H, Eskildsen SF, Borghammer P, Hinz R, Aanerud J, Brooks DJ.
    Neurobiol Dis; 2018 Sep 01; 117():211-216. PubMed ID: 29902557
    [Abstract] [Full Text] [Related]

  • 14. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
    Park JC, Han SH, Yi D, Byun MS, Lee JH, Jang S, Ko K, Jeon SY, Lee YS, Kim YK, Lee DY, Mook-Jung I.
    Brain; 2019 Mar 01; 142(3):771-786. PubMed ID: 30668647
    [Abstract] [Full Text] [Related]

  • 15. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, Mak E, Nicastro N, Bevan-Jones WR, Su L, Hong YT, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB.
    Brain; 2020 May 01; 143(5):1588-1602. PubMed ID: 32380523
    [Abstract] [Full Text] [Related]

  • 16. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA, Benedet AL, Tudorascu DL, Therriault J, Mathotaarachchi S, Savard M, Lussier FZ, Tissot C, Chamoun M, Kang MS, Stevenson J, Massarweh G, Guiot MC, Soucy JP, Gauthier S, Rosa-Neto P.
    Brain; 2021 Dec 16; 144(11):3517-3528. PubMed ID: 34515754
    [Abstract] [Full Text] [Related]

  • 17. Do Tau Deposition and Glucose Metabolism Dissociate in Alzheimer's Disease Trajectory?
    Nowell J, Raza S, Livingston NR, Sivanathan S, Gentleman S, Edison P.
    J Alzheimers Dis; 2024 Dec 16; 101(3):987-999. PubMed ID: 39302365
    [Abstract] [Full Text] [Related]

  • 18. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ, Koscik RL, Jonaitis EM, Allison SL, Cody KA, Erickson CM, Rowley HA, Stone CK, Mueller KD, Clark LR, Carlsson CM, Chin NA, Asthana S, Christian BT, Johnson SC.
    Brain; 2020 Jan 01; 143(1):320-335. PubMed ID: 31886494
    [Abstract] [Full Text] [Related]

  • 19. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Parbo P, Ismail R, Hansen KV, Amidi A, Mårup FH, Gottrup H, Brændgaard H, Eriksson BO, Eskildsen SF, Lund TE, Tietze A, Edison P, Pavese N, Stokholm MG, Borghammer P, Hinz R, Aanerud J, Brooks DJ.
    Brain; 2017 Jul 01; 140(7):2002-2011. PubMed ID: 28575151
    [Abstract] [Full Text] [Related]

  • 20. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
    Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, Salloway S, Doraiswamy PM, Southekal S, Arora AK, McGeehan A, Lim NC, Xiong H, Truocchio SP, Joshi AD, Shcherbinin S, Teske B, Fleisher AS, Mintun MA.
    Brain; 2019 Jun 01; 142(6):1723-1735. PubMed ID: 31009046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.